[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smoking-cigarette\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smoking-cigarette":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,50,87,114,144,164,187,213,238,261,293,318,340],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100609948","phase-2-glp-1-receptor-agonists-to-decrease-ethanol-and-cvd-risk-in-hiv-100609948",false,"NCT07221214","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV","GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV - GL1DER HIV RCT","GL1DER HIV RCT","Inclusion Criteria:\n\n* Ages 18-89\n* Prior diagnosis of HIV-1\n* Affiliated with Vanderbilt Comprehensive Care Clinic\n* On current ART regimen for at least 90 days prior to study entry with no missed doses for at least 7 consecutive days.\n* Most recent absolute CD4 count ≥ 300 cells\u002Fmm3 and drawn within 12 months of study enrollment\n* BMI ≥ 23 (calculated at screening)\n* Self-report of consuming alcohol in past 90 days\n* AUDIT-C ≥ 3 (male)\u002F ≥ 2 (female)\n* Has an established stable address at which they can receive mail and can be reached for the next 6 months\n* Willing and able to complete study procedures and follow-ups\n\nExclusion Criteria:\n\n* Known allergy to semaglutide\n* Currently taking GLP-1 RA (in the past 3 months)\n* History of diabetes defined by diagnosis in Problems List in medical record\n* History of pancreatitis\n* History of gastroparesis\n* Gallbladder disease (in the past 3 months)\n* History of medullary thyroid carcinoma\n* Family history of medullary thyroid carcinoma\n* History of multiple endocrine neoplasia syndrome type 2\n* Family history of multiple endocrine neoplasia syndrome type 2\n* Cognitive inability to consent\n* Barrier to speaking, hearing, reading, or writing English\n* Pregnant or breastfeeding, or planning to become pregnant in the next 6 months\n* Too ill to complete study procedures","ALL","18 Years","89 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The goal of this clinical trial is to learn if the drug semaglutide works to reduce alcohol intake among adults living with HIV. The main questions it aims to answer are:\n\n1. Does semaglutide lower the average number of alcoholic beverages participants drink per week?\n2. Does semaglutide lower the average number of cigarettes participants smoke per day?\n3. Does semaglutide decrease the risk for cardiovascular disease among people living with HIV who drink alcohol and\u002For smoke tobacco?\n\nResearchers will compare the effects of semaglutide to a placebo (a look-alike substance that contains no drug) to see if semaglutide works to lower the alcohol intake among participants each week.\n\nParticipants will:\n\n1. Take semaglutide for 3 months\n2. Visit the research clinic 3 times for checkups and tests\n3. Provide blood samples, stool samples, and saliva samples for tests.",[28,29,30,31],"HIV","Alcohol","Smoking Cigarette","Cardiovascular Disease Prevention",[28,33,34,35,36],"alcohol","smoking","tobacco","cardiovascular disease","RECRUITING","2026-05-22",{"date":40,"type":41},"2026-05-26","ACTUAL",{"date":43,"type":41},"2026-04-17",{"date":45,"type":22},"2030-01-31",{"name":47,"class":48},"Vanderbilt University Medical Center","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":49},"100557265","the-efficacy-of-conventional-screening-versus-mhealth-screening-in-early-detection-of-oral-potentially-malignant-disorders-and-oral-cancer-amongst-the-rural-population-of-varanasi-a-prospective-and-blinded-study-100557265","NCT06535867","The Efficacy of Conventional Screening Versus mHealth Screening in Early Detection of Oral Potentially Malignant Disorders and Oral Cancer Amongst the Rural Population of Varanasi: A Prospective and Blinded Study","Inclusion Criteria:\n\nPositive for any one or more of the following:\n\n* All individuals aged above 18 years positive for habits (smoking and smokeless tobacco, chewing betel leaf, areca nut, paan masala, and\u002For regular use of alcohol)\n* Clinical signs\u002Fsymptoms (non-healing ulcers, white\u002F red\u002Fred \\& white patches in the mouth, restriction of mouth opening and swelling of the neck)\n* All individuals aged above 40 irrespective of habit\u002Foral lesions\n\nExclusion Criteria:\n\n* Individuals already diagnosed with oral cancer and undergoing treatment for oral cancer\n* Under treatment for tuberculosis or suffering from any acute illness\u002F debilitating systemic disorders",true,{"count":58,"type":22},5122,"OBSERVATIONAL","Mobile health (mHealth) will be used for early detection of oral cancer and pre-cancer lesions, and to improve awareness of oral cancer among the population and knowledge of oral cancer diagnosis among frontline health providers. This program is inclusive of long term surveillance to downstage oral cancer in India",[62,63,64,65,66,67,68,69],"Smoking","Smoking, Cigarette","Smoking, Tobacco","Betel Chewer's Mucosa","Tobacco Use","Tobacco Smoking","Alcohol Drinking","Smokeless Tobacco Hyperkeratosis",[34,71,72,73,74,75,76,77,78,79],"smoking, cigarette","smoking, tobacco","smokeless tobacco","betel leaf","areca nut","paan masala","alcohol use","Memorial Sloan Kettering Cancer Center","24-148","2026-05-19",{"date":38,"type":41},{"date":83,"type":41},"2024-07-30",{"date":85,"type":22},"2031-07-30",{"name":78,"class":48},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100538900","phase-2-dyadic-financial-incentive-treatments-for-dual-smoker-couples-100538900","NCT06296849","Dyadic Financial Incentive Treatments for Dual Smoker Couples","Randomized Controlled Trial of Dyadic Financial Incentive Treatments for Dual Smoker Couples: Evaluation of Efficacy, Mechanisms, and Cost Effectiveness (1R01CA276594-01A1)","Inclusion Criteria:\n\n* 1\\) age of 18+; 2) smoking of 5+ cigarettes\u002Fday; 3) relationship status of married to or living with a daily smoker of 5+ cigarettes who is also above the age of 18; and 4) romantic relationship duration of at least six months.\n\nExclusion Criteria:\n\n* 1\\) less than 8th grade capacity to read and write in English; 2) recent hospitalization (past 6 months) 3) psychosis risk; 4) regular (4+ days weekly) use of e-cigarettes; 5) Contra-indication for NRT (e.g., pregnancy, heart disease); 6) Marijuana use.\n\nInclusion and exclusion criteria apply to both members of each couple; both members of each couple must be eligible for the target to enroll.",{"count":95,"type":22},900,[25],"Smokers partnered with other smokers (i.e., dual-smoker couples) represent \\~2\u002F3 of all smokers. Dual-smoker couples (DSCs) are less likely to try to quit smoking and more likely to relapse during a quit attempt, reducing overall smoking cessation rates and representing a high-risk clinical population. Despite their high prevalence and risk for persistent smoking, however, there are limited data on smoking cessation interventions among DSCs. Building on previous research that suggests a) financial incentive treatments (FITs) are effective at increasing quit rates and b) dyadic adaptations of FITs are feasible for implementation in DSCs, the proposed study will systematically two versions of FITs to enhance smoking cessation among DSCs. In addition to determining the efficacy of these dyadic FITs for smoking abstinence in DSCs, the investigators will consider the cost and cost effectiveness of each adaptation as well as mechanisms of change to inform future implementation research. The investigators will additionally consider secondary outcomes including abstinence during treatment and long-term abstinence maintenance after end of treatment.\n\nThe investigators will address these questions in a three-group randomized controlled trial (RCT). In all conditions, individuals who have smoking partners (i.e., targets) will receive usual care (combination fast and slow acting Nicotine Replacement Therapy + quitting resources). In two conditions, participants will receive incentives for abstinence at three time points (1, 3, and 6 months post-baseline). In the SFIT condition, only the target in a couple will be offered incentives; in the DFIT condition, both target and partner will be offered incentives. Primary efficacy outcome is % point-prevalence abstinence at 6 months post-baseline among targets. Secondary outcomes are point-prevalence abstinence at 1 and 3 months during the treatment and 6 months post-treatment (12-months post-baseline), as well as partner outcomes. The investigators will evaluate possible mechanisms of change including partner support and individual and partner motivation to quit as well as evaluate the cost and relative cost of each abstainer within and across condition. These data on the efficacy, mechanisms, and costs of FITs for DSCs will inform population level implementation and promote successful quitting in this treatment refractory population.",[63],[100,101,102,103],"smoking cessation","dual-smoker couples","behavioral economics","financial incentives","2026-04-27",{"date":106,"type":41},"2026-04-29",{"date":108,"type":41},"2024-01-18",{"date":110,"type":22},"2028-05",{"name":112,"class":48},"University of Oklahoma",2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":56,"sex":121,"minAge":18,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":126,"conditions":127,"keywords":133,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":49},"100602905","trauma-informed-care-for-smoking-cessation-for-pregnancy-100602905","NCT07129590","Trauma-Informed Care for Smoking Cessation for Pregnancy","TRauma-Informed Care in Smoking cEssation for Pregnancy (RISE Pregnancy)","Inclusion Criteria:\n\nClinician Eligibility Criteria (Aims 1 - 3):\n\nIn Aims 1-3, will be recruiting clinicians working in our clinic sites.\n\n1. Nurse practitioner, physician assistant, nurse-midwife, medical doctor, registered nurse, clinical pharmacist, behavioral health professional, social worker, or any other healthcare professional caring for pregnant patient-participants.\n2. Age ≥ 18 years old.\n\nPatient-participant Eligibility Criteria (Aim 1):\n\nIn Aim 1, will be recruiting pregnant women (ages 18+) who:\n\n1. Currently smoking or report having smoked during a previous pregnancy\n2. Age ≥18 years old.\n3. Currently Pregnant.\n4. Identifies as a cisgender woman, or female at birth.\n5. Reports having experienced trauma aligned with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) definition for traumatic exposure.\n6. Proficient in English or Spanish languages.\n\nPatient-Participant Eligibility Criteria (Aim 2):\n\nPatient-participants will be recruited to give feedback on our intervention using Evidence-Based Quality Improvement (EBQI) meetings.\n\nInclusion criteria:\n\n1. Current or former patient in the participating clinical sites.\n2. Age ≥18 years old.\n3. Proficient in English or Spanish languages.\n\nPatient-Participant Eligibility Criteria (Aim 3): In Aim 3, will be recruiting pregnant women who are actively smoking and have histories of trauma (ages 18+).\n\nInclusion criteria:\n\n1. Currently smoking (ever smoked 100 cigarettes in their lifetime, smoked in the past 7 days and at least 1 cigarette per day, verified by CO≥6ppm)\n2. ≥18 years old\n3. Currently Pregnant\n4. Identifies as a cisgender women, or female at birth\n5. Meets DSM-5 Criterion A for trauma exposure on the Brief Trauma Questionnaire (BTQ)\n6. English or Spanish Proficient\n\nExclusion Criteria:\n\nClinician- and Patient-participant Exclusion criteria (Aims 1 - 3):\n\n1\\. Any condition, including active mental health crises or cognitive impairment, that would interfere with the ability to provide informed consent or safely complete the study.","FEMALE",{"count":123,"type":22},20,[125],"NA","Trauma-informed approaches have been shown to support recovery from other substance use disorders and involve four key elements: (1) Realizing the prevalence of trauma and pathways to recovery, (2) Recognizing symptoms of trauma, (3) Responding by embedding knowledge of trauma into practices and policies and (4) Resisting re-traumatization (the 4Rs). In close partnership with Breathe California and a public safety-net clinic in San Francisco that serves primarily racial and ethnic minoritized (REM) pregnant women, the 4Rs along with the Ask, Advise, Assess, Assist and Arrange (the 5As) evidence-based intervention for tobacco cessation that is delivered by health care professionals and is a US Public Health Services clinical practice guideline for treating tobacco will be used to create and implement a smoking cessation intervention for pregnant women with experiences of trauma.",[128,67,129,130,63,131,132],"Smoking Cessation","Tobacco Use Cessation","Smoking Reduction","Trauma, Psychological","Trauma and Stressor Related Disorders",[134],"Pregnancy","2026-04-20",{"date":137,"type":41},"2026-04-23",{"date":139,"type":41},"2025-11-19",{"date":141,"type":22},"2026-07-31",{"name":143,"class":48},"University of California, San Francisco",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":49},"100490007","leveraging-community-pharmacists-to-optimize-smoking-cessation-services-for-rural-smokers-in-appalachia-100490007","NCT05660525","Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia","Study participants will be rural cigarette smokers from Virginia, Tennessee, Kentucky and North Carolina who visit one of the participating study pharmacies. Pharmacies will be located in rural geographic areas of the Central and South Central subregions of Appalachia that include Virginia, Tennessee, Kentucky and North Carolina, as defined by the USDA Rural-Urban Continuum Codes (RUCC) 4-9, Rural-Urban Commuting Area (RUCA) codes 4-10, or Frontier and Remote (FAR) areas level 4. No exclusionary criteria are based on race, gender, or age.\n\nInclusion Criteria include:\n\n* must be 18 years of age and older\n* must be able to read, speak, and understand English\n* must report smoking at least 5 cigarettes per day for the past 6 months (regardless of non-cigarette tobacco product use)\n* must be willing to set a quit date within the next 30 days\n* must own a cell phone\n* must be willing and able to use NRT in the form of patch or lozenge\n* Not be pregnant or planning to be pregnant in the next 6 months.\n\nExclusion Criteria include:\n\n* are pregnant women (self-reported), breastfeeding, planning to become pregnant during the next 6 months\n* have a medical contraindication to NRT (e.g., past 30 days, heart attack or stroke; past 6 months, serious or worsening angina, very rapid or irregular heartbeat requiring medication)",{"count":151,"type":22},768,[125],"The goal of this clinical trial is to evaluate the effectiveness and implementation of a pharmacist-delivered MTM (medication therapy management) approach, called QuitAid, to quitting cigarette smoking in rural Appalachia.\n\nThe main questions it aims to answer are:\n\n* Is QuitAid, alone or combined with other quitting tobacco treatments, effective?\n* What makes QuitAid easy or hard to carry out? Is it cost effective? Is it easy to maintain?\n\nTreatment:\n\nAll participants will be given at least 4 weeks of the nicotine patch.\n\nSome participants will be randomized (like the flip of a coin) to receive additional treatments (listed below).\n\nThese groups will be compared to each other to see which combination works best to help them quit smoking.\n\n* Smokefree TXT - a texting program that helps people quit smoking\n* Tobacco quitline - 4 phone sessions to help people quit smoking\n* 8 weeks of NRT (nicotine replacement therapy in the form of nicotine patches or nicotine patches and lozenge) medication instead of 4 weeks\n* QuitAid - An MTM program given by the patient's pharmacist. This is a quitting smoking coaching program\n* Nicotine patch AND nicotine lozenge instead of just nicotine patches",[128,63,130,62,64,155],"Quitting Smoking","2026-04-16",{"date":135,"type":41},{"date":159,"type":41},"2024-03-06",{"date":161,"type":22},"2028-03-01",{"name":163,"class":48},"University of Virginia",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":49},"100630038","university-of-michigan-copd-identification-through-lung-cancer-screening-cohort-study---map2-100630038","NCT07482475","University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2","MAP2","Inclusion Criteria:\n\n* Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent.\n* Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials.\n* Ability to tolerate study procedures.\n* Ability to provide informed consent.\n* Clinical Lung Cancer Screening CT performed at the University of Michigan within the last year\n* Meets one of the three following criteria:\n\n  1. Prior Diagnosis of COPD in the EMR\n  2. Prior pulmonary function meeting criteria for COPD (FEV1\u002FFVC ≤ 0.70) or\n  3. LAA\\>1% on lung cancer screening CT scan\n\nExclusion Criteria:\n\n* The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance).\n* Severe asthma, which is defined as any of the following:\n\nCurrent (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS\u002FLABA or high dose ICS or add-on LAMA; Medium dose = \\>250 fluticasone propionate =100 fluticasone furoate, \\>200 beclomethasone, \\>400 budesonide, \\>220 mometasone). The investigators will accept low-dose ICS\u002FLABA or medium dose ICS.\n\nor 3 or more unscheduled healthcare visits (provider\u002Furgent care\u002FER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months\n\n* Concurrent participation in a therapeutic trial where treatment is blinded.\n* Active pregnancy. Documentation of birth control will be required for pre-menopausal women.\n* Cognitive dysfunction that prevents the participant from completing study procedures.\n* BMI \\> 35 kg\u002Fm2 at baseline, due to the effects of body weight on CT scan quality.\n* Current illicit substance abuse, including cannabis smoking.\n* Any illness expected to cause mortality in the next 3 years.\n* Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan quality.\n* History of thoracic radiation or thoracic surgery with resection of lung tissue.\n\nAdditional temporal exclusion criteria are as follows:\n\n* Participants who present with an acute exacerbation of COPD, either solely participant-identified or that has been clinically treated, in the last 30 days can be rescreened for the study once the 30-day window from end of drug therapy has passed.\n* Participants who present with current use of acute antibiotics or steroids can be rescreened for the study ≥30 days after discontinuing acute antibiotics\u002Fsteroids. This restriction does not apply to participants who are on chronic prednisone therapy of \\\u003C10 mg per day or \\\u003C20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy.","50 Years","80 Years",{"count":21,"type":22},"The purpose of this study is to obtain new knowledge regarding screening for COPD. This study will use a participant's cancer screening CT scans performed as part of routine health care among current and former smokers at risk for COPD to identify participants who have had a spirometry or will have a spirometry test as part of the study to verify COPD status.",[176,177,30],"COPD (Chronic Obstructive Pulmonary Disease)","Cancer Lung Screening","2026-03-21",{"date":180,"type":41},"2026-03-25",{"date":182,"type":41},"2025-07-15",{"date":184,"type":22},"2026-12",{"name":186,"class":48},"University of Michigan",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":23,"phases":197,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":113},"100588724","act-lung-health-intervention-phase-two-100588724","NCT06945120","ACT Lung Health Intervention: Phase Two","Efficacy of an Asian Culture-tailored Lung Health (ACT) Intervention on Lung Cancer Screening and Smoking Cessation in Asian Americans","Inclusion Criteria:\n\n* Self-identify as either Chinese or Korean\n* Speak either Korean, Mandarin, or English\n* Are 18 years of age or older\n* Are current smokers (i.e., have smoked at least 100 traditional cigarettes ever and have smoked at least one traditional cigarette within the prior 30 days)\n* Will live in the United States for the next 12 months\n\nExclusion Criteria:\n\n* Hospitalization due to a serious mental illness (e.g., psychotic disorders) during the prior 6 months.\n* We will not include any of the following special populations:\n\n  * Adults unable to consent.\n  * Adults younger than 50 or older than 80 years\n  * Individuals who are not yet adults (infants, children, teenagers)\n  * Pregnant women\n  * Prisoners","100 Years",{"count":196,"type":22},50,[125],"This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.",[128,200,64,63,201],"Smoking Behaviors","Smoking (Tobacco) Addiction",[128,203,201,63,64,200],"Lung Cancer Screening","2026-03-11",{"date":206,"type":41},"2026-03-13",{"date":208,"type":41},"2025-11-04",{"date":210,"type":22},"2026-12-31",{"name":212,"class":48},"Dana-Farber Cancer Institute",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":49},"100621558","wound-healing-following-extraction-and-ridge-preservation-in-smokers-and-non-smokers-100621558","NCT07372183","Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers","Inclusion Criteria:\n\n* Adult patients (18-75 years)\n* Good general health (controlled conditions)\n* Smokers (≥10 cigarettes\u002Fday for ≥5 years) and never smokers. Confirmation of smoking status will be done via use of a smokerlyzer. The cut-off point for distinguishing smokers from non-smokers is 8 carbon monoxide parts per million (ppm).\n* Periodontal status: periodontal health, gingivitis on intact or reduced periodontium, treated periodontitis\n* Intact post-extraction bony walls or less than 50% bone dehiscence\n* Distance at least 8 mm of vertical bone height between bone crest and anatomical structures (i.e. sinus floor, inferior alveolar nerve (IAN) canal, mental foramen)\n* Extracted tooth root in the same three-dimensional position as the future implant placement so that the bone core biopsy can be taken from a site totally within the confines of the former tooth socket without inclusion of surrounding native alveolar bone\n* Scheduled for single tooth extraction with bone graft placement and membrane\n\nExclusion Criteria:\n\n* Uncontrolled periodontal disease\n* Uncontrolled systemic disease\n* Pregnancy\n* Use of therapy and\u002For medication that impairs wound healing (e.g., bisphosphonates, steroids, chemotherapy, radiotherapy etc.)","75 Years",{"count":221,"type":22},12,"The goal of this study is to evaluate bone wound healing following extraction and alveolar ridge preservation (bone graft and membrane) clinically, histologically and in relation to gene expression in smokers and non-smokers. Data from a small group of participants will be analyzed after age-matched subjects undergo extraction and alveolar ridge preservation prior to implant placement. The data obtained in this pilot study will be used to plan a full-fledged study involving a larger number of smoking and non-smoking participants to compare the two groups.",[63,224,225,226,227],"Alveolar Bone Grafting","Wound Healing","Bone Healing","Tooth Extraction Site Healing","NOT_YET_RECRUITING","2026-01-20",{"date":231,"type":41},"2026-01-28",{"date":233,"type":22},"2026-01-25",{"date":235,"type":22},"2028-10-01",{"name":237,"class":48},"Marquette University",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":244,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":49},"100440760","optimizing-tobacco-treatment-delivery-for-people-living-with-hiv-100440760","NCT05019495","Optimizing Tobacco Treatment Delivery for People Living With HIV","Inclusion Criteria:\n\n* Age 21 and older\n* Current diagnosis of HIV\n* Current smoker (defined as self-report of current smoking)\n* Willing to be randomized\n* English speaking\n\nExclusion Criteria:\n\n* Currently taking part in any other tobacco treatment program or using cessation medication (i.e., taking nicotine replacement therapy or other cessation medications, enrolled in the Quitline, or in another study)\n* Currently imprisoned\n* Pregnant women\n* Non-English speaking persons","21 Years",{"count":246,"type":22},231,[125],"The purpose of this study is to conduct a randomized trial to evaluate a proactive, opt-out model of provider contact to deliver smoking cessation support for people living with HIV compared to standard care support delivered through traditional clinic pathways. Investigators will also evaluate implementation outcomes to identify barriers and facilitators towards future implementation. Investigators hope to define best practices and optimize the delivery of smoking cessation interventions for people living with HIV.",[250,63],"Hiv",[62],"2026-01-02",{"date":254,"type":41},"2026-01-06",{"date":256,"type":41},"2021-12-01",{"date":258,"type":22},"2027-02-28",{"name":260,"class":48},"Medical University of South Carolina",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":292},"100569396","a-study-evaluating-the-use-of-an-indoor-air-quality-monitor-to-promote-a-smoke-free-home-100569396","NCT06693700","A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home","Freedom to Breathe: Pilot Study Towards Achieving Environmental Justice for Cancer Patients and Their Families","Inclusion Criteria:\n\n* Adult (aged \\>18 years) MSK patients as per the EHR\n* Has been referred and enrolled in the MSK TTP and completed the initial counseling session as per the TTP clinical database\n* Reports current (within the past 30 days) tobacco use (i.e., cigarettes and\u002For any other tobacco products) as per the TTP Intake form\n* Must be English-speaking in the EHR\n* Must be reachable by phone as per self-report\n* Must have Wi-Fi available at home as per self-report\n\nExclusion Criteria:\n\n* Patient reports that no smoking is allowed, by them or anyone else, in the home as per the TTP intake form and\u002For per self-report",{"count":269,"type":22},10,[125],"The purpose of this study is to evaluate how using an indoor air quality monitor can promote a smoke-free home for cancer patients who are enrolled in MSK's Tobacco Treatment Program.",[62,128,130,273,200,64,63,201,66,67],"Smoking Habit",[34,100,275,276,277,72,71,278,279,280,281,282,283,78],"smoking reduction","smoking habit","smoking behaviors","smoking (tobacco) addiction","tobacco use","tobacco smoking","air quality","indoor air quality monitoring devices","24-260","2025-10-21",{"date":286,"type":41},"2025-10-22",{"date":288,"type":41},"2024-11-14",{"date":290,"type":22},"2027-11-14",{"name":78,"class":48},8,{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":56,"sex":17,"minAge":18,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":49},"100341150","phase-1-imaging-sex-differences-in-smoking-induced-pulmonary-inflammation-100341150","NCT03721822","Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation","Measurement of Pulmonary Inflammation Using 18F-NOS Positron Emission Tomography (PET\u002FCT) in E-cigarette Users","Inclusion Criteria:\n\n1. Participants will be 18-45 years of age\n2. Subject must meet one of the following criteria:\n\n   NIC vapers: current e-cigarette use of nicotine at least 5 days per week for the past year, no current combustible cigarette use, cannabis vaping, or cannabis smoking during the 30 days prior to study enrollment\n\n   CAN vapers: current e-cigarette use of cannabis at least 5 days per week for the past year, no current combustible cigarette use, cannabis smoking, or nicotine vaping during the 30 days prior to study enrollment\n\n   Cigarette smokers: current cigarette smoking of at least 5 cigarettes per day, 4 days per week for the past year with no e-cigarette use (cannabis or nicotine) during the 30 days prior to study enrollment\n\n   Dual combustible and e-cigarette users: current e-cigarette use of cannabis and\u002For nicotine at least 5 days per week for the past year with cigarette or cannabis smoking during the 30 day prior to study enrollment\n\n   Non-Smokers: reported non-smoking history or \\\u003C 100 lifetime cigarettes, \\\u003C 100 e-cigarette use episodes, and \\\u003C 100 lifetime cannabis use episodes\n3. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening and on scan day.\n2. Current untreated and unstable diagnosis of substance use disorder, except nicotine use disorder or cannabis use disorder\n3. Positive urine drug screen for opiates, methamphetamine or cocaine at screening\n4. Current unstable and\u002For untreated major depression or psychotic disorder per medical record review or self-reported\n5. Use of inhaled or oral corticosteroids or anti-inflammatory medications per medical record review or self-report\n6. History of lung trauma\n7. Active (or within the previous 4 weeks of screening) lung infection or lung disease that impact uptake of \\[18F\\]NOS (e.g. tuberculosis, cystic fibrosis)\n8. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician\n9. Any current or past medical condition, illness, or disorder as assessed by medical record review and\u002For self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study","45 Years",{"count":302,"type":22},100,[304],"PHASE1","The purpose of this research is to measure the extent of lung inflammation between different groups of participants using a radioactive tracer called \\[18F\\]NOS. A radioactive tracer is a type of imaging drug that is labeled with a radioactive tag and injected into the body.",[63,307,308],"Smoking E-cigarette","Healthy Volunteer","2025-09-29",{"date":311,"type":41},"2025-10-03",{"date":313,"type":41},"2018-10-23",{"date":315,"type":22},"2026-10-23",{"name":317,"class":48},"University of Pennsylvania",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":56,"sex":121,"minAge":18,"maxAge":325,"enrollmentInfo":326,"targetDuration":4,"studyType":23,"phases":328,"briefSummary":329,"conditions":330,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":338,"locationsCount":49},"100325253","maternal-smoking-cessation-and-pediatric-obesity-prevention-100325253","NCT03514602","Maternal Smoking Cessation and Pediatric Obesity Prevention","Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation","Inclusion Criteria:\n\n1. Able to read, understand, and speak English.\n2. Are 18-39 years old\n3. Are less than 20 weeks of gestation\n4. Have a singleton pregnancy\n5. Currently smoking one or more cigarettes per day, based on self-report.\n6. Currently smoking biochemically verified by a level of 1 or higher in urine cotinine test (i.e., \\>100ng\u002FmL cotinine concentration).\n7. Willing to try to quit or reduce smoking by behavioral intervention\n8. Willing to monitor smoking status by breath carbon monoxide and saliva cotinine.\n9. Willing to provide breath, saliva, and urine samples to test smoking status\n10. With low household income (meeting federal income eligibility guidelines for the Special Supplemental Nutrition Program for Women, Infants, and Children) and\u002For low education level (≤12 years). These disadvantaged pregnant women are very likely not to quit spontaneously, and thus need extra intervention most.\n11. Currently living in Erie County or Niagara County; don't plan to move out of these two counties during the current pregnancy.\n\nExclusion Criteria:\n\n1. Previous history of major chronic disease or blood clotting disorders such as cancer, thyroid disorders, heart disease, kidney disease\n2. Depression or have been diagnosed with depression or post-partum depression at any time\n3. In treatment for Axis 1 disorders that prevent them following smoking cessation interventions","39 Years",{"count":327,"type":22},48,[125],"The objective of this study is to test the effect of smoking cessation in pregnancy or in lactation on preventing rapid infant adiposity gain. Investigators propose a randomized, controlled experiment among smoking pregnant women from 1st prenatal care visit through 6 months of postpartum period. Two-phase randomization will be applied to separate the effects of smoking cessation in two different critical periods (i.e., pregnancy and lactation) on infant adiposity gain. Investigators will first randomly assign 40 smoking pregnant women into either the multicomponent intervention (N=30) or the education-only control group (N=10). The multicomponent intervention group will receive education and counseling, monitoring and feedback, contingent financial incentives, and family support, while the control group will receive education only. At the end of pregnancy, investigators will further randomize successful quitters (estimated N=20) from the multi-component intervention group into either the continuous multi-component intervention group in lactation (N=10) or the education-only control group (N=10). All women and their newborns will be followed from enrollment to 6 months postpartum. The key outcomes include maternal smoking abstinence confirmed by urine-cotinine and infant gain in weight-for-length z-score. Specific Aim 1 is to examine the effects of maternal smoking cessation intervention in pregnancy on infant gain in weight-for-length z-score from birth to 6 months. Specific Aim 2 is to examine the effect of maternal smoking abstinence intervention in lactation and infant post-weaning gain in weight-for-length z-score among the women who have successfully quit smoking in pregnancy.",[331,63,134],"Childhood Obesity","2025-07-25",{"date":334,"type":41},"2025-07-30",{"date":336,"type":41},"2015-07-01",{"date":210,"type":22},{"name":339,"class":48},"State University of New York at Buffalo",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":347,"enrollmentInfo":348,"targetDuration":350,"studyType":59,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":228,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":4},"100574126","impact-of-smoking-on-ultrasound-guided-infraclavicular-brachial-plexus-block-onset-and-duration-100574126","NCT06755229","Impact of Smoking on Ultrasound-Guided Infraclavicular Brachial Plexus Block Onset and Duration","Does Smoking Affect the Onset and Duration of Ultrasound-guided Infraclavicular Brachial Plexus Block?","Inclusion Criteria:\n\n* ASA physical status I and II\n* Scheduled for acute or elective hand or forearm surgery under the lateral infraclavicular block\n\nExclusion Criteria:\n\n* morbid obesity (body mass index \\> 40)\n* bleeding disorder\n* coagulopathy\n* medication with vitamin K antagonists\n* high-dose or fractionated heparin treatment\n* allergy to local anaesthetics\n* infection at the site of needle insertion\n* peripheral neurological disease\n* pregnancy","65 Years",{"count":349,"type":22},40,"1 Day","The present study will be conducted involving 40 patients aged 18-65 years with ASA physical status I and II, scheduled for acute or elective hand or forearm surgery under the lateral infraclavicular block. Patients will be divided into two groups based on smoking status: Group I (non-smokers) and Group II (smokers who smoke ≥20 cigarettes\u002Fday for over 1 year).\n\nUsing a high-frequency linear ultrasound transducer, the axillary artery, vein, and the three nerve cords will be identified in the lateral infraclavicular region. After disinfection with ethanol-chlorhexidine, a sterile drape will be placed, and the attending anesthesiologist will perform the ultrasound-guided infraclavicular brachial plexus block with a triple injection technique. A total of 10 mL of bupivacaine 0.25% and prilocaine 0.05% will be injected at all three nerve cords.\n\nThe primary outcome will be the sensory blockade onset time, while secondary outcomes will include the duration of sensory and motor blockade, motor blockade onset time, time to first postoperative rescue analgesia, and total consumption of rescue analgesia. Postoperative pain will be assessed using the Visual Analogue Scale (VAS) within the first 24 hours at intervals of 2, 4, 8, 12, 16, and 24 hours. If VAS exceeds 30 cm, rescue analgesia with 0.05 mg\u002Fkg intravenous morphine sulfate will be administered.",[63,353],"Regional Anesthesia","2024-12-24",{"date":356,"type":41},"2025-01-01",{"date":358,"type":22},"2025-01-15",{"date":360,"type":22},"2025-03-20",{"name":362,"class":48},"Selcuk University"]